Uffmann, Madita <br/><br/>
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.  [electronic resource] 

 -  Blood  06 2017 
 - 3314-3321 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2017-01-765057  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Child, Preschool<br/>Chromosomes, Human, Pair 8--genetics<br/>Cytarabine--adverse effects<br/>Cytogenetic Analysis<br/>Disease-Free Survival<br/>Down Syndrome--complications<br/>Etoposide--adverse effects<br/>Female<br/>Humans<br/>Idarubicin--adverse effects<br/>Infant<br/>Leukemia, Myeloid--complications<br/>Male<br/>Prospective Studies<br/>Treatment Outcome<br/>Trisomy--genetics